Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858573 | 0.91 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1CYP1A2GAACYP2C9 | |
| SCHEMBL3861721 | 0.76 | AURKA (0.47) | NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3819537 | 0.74 | KDM4E (0.38) | SMN1; SMN2ALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL1263492 | 0.73 | HPGD (0.50) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL742843 | 0.71 | LMNA (0.47) | P2RY14ALDH1A1ADORA3CYP1A2CYP2C9 | |
| SCHEMBL18529056 | 0.71 | PKM (0.43) | SMN1; SMN2ALDH1A1CYP1A2CYP2C9HPGD | |
| SCHEMBL1262155 | 0.70 | KDM4E (0.42) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL1262158 | 0.70 | KDM4E (0.42) | SMN1; SMN2ALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL4632621 | 0.70 | HDAC6 (0.53) | P2RY14SMN1; SMN2ALDH1A1ADORA3CYP1A2 | |
| SCHEMBL739840 | 0.70 | ADORA3 (0.40) | P2RY14SMN1; SMN2ALDH1A1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595320-B2 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-7595320-B2 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| US-7595320-B2 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, process for preparing them, compositions containing them and use thereof | AVENTIS PHARMA S.A. (FR) | 2009-09-29 | — | — | US | disclosed |
| EP-1858898-B1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2009-08-26 | — | — | EP | disclosed |
| EP-1858898-B1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA SA (FR) | 2009-08-26 | — | — | EP | disclosed |
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-19 | — | — | US | disclosed |
| EP-1858898-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | Aventis Pharma S.A. (FR) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006092510-A1 | HYDRAZINOCARBONYL-THIENO[2,3-C]PYRAZOLES, PREPARATION METHOD, COMPOSITIONS CONTAINING SAME AND USE | AVENTIS PHARMA S.A. (FR) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146542-A1 | Hydrazinocarbonyl-thieno[2,3-C]pyrazoles, Process for Preparing Them, Compositions Containing Them and Use Thereof | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CASP3 | P2RY14 1264/4885SMN1; SMN2 3109/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.